

Jaswinder Samra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10458838/publications.pdf>

Version: 2024-02-01

32
papers

676
citations

623734

14
h-index

580821

25
g-index

32
all docs

32
docs citations

32
times ranked

1335
citing authors

#	ARTICLE	IF	CITATIONS
1	Pain management, fluid therapy and thromboprophylaxis after pancreatoduodenectomy: a worldwide survey among surgeons. <i>Hpb</i> , 2022, 24, 558-567.	0.3	4
2	Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. <i>Journal of Proteomics</i> , 2021, 231, 103998.	2.4	10
3	Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma. <i>The Cochrane Library</i> , 2021, 2021, CD011490.	2.8	6
4	Gallbladder carcinoma outcomes in an Australian tertiary referral hospital. <i>ANZ Journal of Surgery</i> , 2021, 91, 603-608.	0.7	3
5	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4172-TPS4172.	1.6	1
6	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2700.	2.4	5
7	How to do a retroperitoneoscopic lumbar sympathectomy. <i>ANZ Journal of Surgery</i> , 2021, 91, 1925-1926.	0.7	0
8	Pancreatic solid pseudopapillary neoplasm: a single institution study. <i>ANZ Journal of Surgery</i> , 2021, 91, 2453-2458.	0.7	4
9	Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: A multicentre observational study. <i>ANZ Journal of Surgery</i> , 2021, 91, 2447-2452.	0.7	3
10	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. <i>BMC Cancer</i> , 2021, 21, 936.	2.6	12
11	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. <i>Science Advances</i> , 2021, 7, eabh0363.	10.3	23
12	Rare anastomosis between a replaced right hepatic artery and left branch of the proper hepatic artery. <i>Surgical and Radiologic Anatomy</i> , 2021, 44, 137.	1.2	2
13	RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020, 33, 657-664.	5.5	22
14	Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188418.	7.4	21
15	PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129682.	2.4	15
16	Asymptomatic thrombosis of extrahepatic portal vein aneurysm necessitating hybrid operative repair. <i>Vascular</i> , 2020, 29, 170853812097697.	0.9	3
17	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020, 33, 1811-1821.	5.5	19
18	Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?. <i>Cancers</i> , 2020, 12, 1341.	3.7	34

#	ARTICLE	IF	CITATIONS
19	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 237.	2.8	22
20	Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. <i>Clinical Endocrinology</i> , 2020, 92, 396-406.	2.4	51
21	Routine NTRK immunohistochemistry is not a useful screening strategy in unselected pancreatic carcinomas. <i>Pathology</i> , 2020, 52, 398-400.	0.6	0
22	Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1539-1542.	1.0	6
23	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , 2019, 21, 444-455.	0.3	20
24	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.	12.1	100
25	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 103.	2.5	7
26	Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. <i>Theranostics</i> , 2017, 7, 1149-1158.	10.0	201
27	Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 107223-107236.	1.8	28
28	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> , 2016, 204, 419-422.	1.7	14
29	Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). <i>PLoS ONE</i> , 2016, 11, e0158140.	2.5	22
30	Extended lymph node resection versus standard resection for pancreatic and peri-ampullary adenocarcinoma. <i>The Cochrane Library</i> , 2015, , .	2.8	1
31	Peroxisome proliferator-activated receptor- β staining is associated with worse outcome in colorectal liver metastases. <i>Molecular and Clinical Oncology</i> , 2015, 3, 308-316.	1.0	9
32	Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. <i>World Journal of Oncology</i> , 2013, 4, 74-82.	1.5	8